Lambert-Eaton myasthenic syndrome (LEMS)

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Lambert-Eaton myasthenic syndrome (LEMS) is a neuromuscular disorder in which autoantibodies inhibit the presynaptic release of acetylcholine. Autoantibodies against P/Q-type voltage-gated calcium channels (VGCC) are detected in 85% of patients with LEMS. In addition, autoantibodies to synaptotagmin, an M1-type muscarinic acetylcholine receptor and SOX1 are also found in the sera of patients with LEMS. LEMS is closely associated with small cell lung cancer (SCLC) in 50-60% of patients. Patients with SCLC who have anti-VGCC antibodies have been reported to have a favorable prognosis. In contrast to paraneoplatic LEMS, other forms of LEMS may have an autoimmune aspect because of the established association between human leukocyte antigen and a family history of other autoimmune disorders in this condition. The clinical features of LEMS include proximal weakness, areflexia, ptosis, cerebellar ataxia and autonomic dysfunction. The findings of electrophysiological examination show that LEMS is characterized by compound muscle action potential potentials with a low amplitude and increment upon repetitive nerve stimulation at a high rate. Tumor removal is the primary treatment of LEMS. The efficacy of 3,4-diaminopyridine for the treatment of LEMS has also been established. Patients with LEMS require the immunotherapies such as plasma exchange and the administration of high doses of immunoglobulin and prednisolone.

Original languageEnglish
Pages (from-to)419-426
Number of pages8
JournalBrain and Nerve
Volume62
Issue number4
Publication statusPublished - 2010 Apr

Fingerprint

Lambert-Eaton Myasthenic Syndrome
Autoantibodies
Small Cell Lung Carcinoma
Calcium Channels
Synaptotagmins
Cerebellar Ataxia
Plasma Exchange
Muscarinic Receptors
HLA Antigens
Prednisolone
Immunotherapy
Action Potentials
Acetylcholine
Immunoglobulins

Keywords

  • Autoantibodies
  • P/Q-type voltage-gated calcium channels
  • Paraneoplastic
  • Small cell lung cancer
  • Synaptotagmin

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Lambert-Eaton myasthenic syndrome (LEMS). / Suzuki, Shigeaki.

In: Brain and Nerve, Vol. 62, No. 4, 04.2010, p. 419-426.

Research output: Contribution to journalArticle

@article{2f1efe855f76470bae8ed46991d38f97,
title = "Lambert-Eaton myasthenic syndrome (LEMS)",
abstract = "Lambert-Eaton myasthenic syndrome (LEMS) is a neuromuscular disorder in which autoantibodies inhibit the presynaptic release of acetylcholine. Autoantibodies against P/Q-type voltage-gated calcium channels (VGCC) are detected in 85{\%} of patients with LEMS. In addition, autoantibodies to synaptotagmin, an M1-type muscarinic acetylcholine receptor and SOX1 are also found in the sera of patients with LEMS. LEMS is closely associated with small cell lung cancer (SCLC) in 50-60{\%} of patients. Patients with SCLC who have anti-VGCC antibodies have been reported to have a favorable prognosis. In contrast to paraneoplatic LEMS, other forms of LEMS may have an autoimmune aspect because of the established association between human leukocyte antigen and a family history of other autoimmune disorders in this condition. The clinical features of LEMS include proximal weakness, areflexia, ptosis, cerebellar ataxia and autonomic dysfunction. The findings of electrophysiological examination show that LEMS is characterized by compound muscle action potential potentials with a low amplitude and increment upon repetitive nerve stimulation at a high rate. Tumor removal is the primary treatment of LEMS. The efficacy of 3,4-diaminopyridine for the treatment of LEMS has also been established. Patients with LEMS require the immunotherapies such as plasma exchange and the administration of high doses of immunoglobulin and prednisolone.",
keywords = "Autoantibodies, P/Q-type voltage-gated calcium channels, Paraneoplastic, Small cell lung cancer, Synaptotagmin",
author = "Shigeaki Suzuki",
year = "2010",
month = "4",
language = "English",
volume = "62",
pages = "419--426",
journal = "Brain and Nerve",
issn = "0006-8969",
publisher = "Igaku-Shoin Ltd",
number = "4",

}

TY - JOUR

T1 - Lambert-Eaton myasthenic syndrome (LEMS)

AU - Suzuki, Shigeaki

PY - 2010/4

Y1 - 2010/4

N2 - Lambert-Eaton myasthenic syndrome (LEMS) is a neuromuscular disorder in which autoantibodies inhibit the presynaptic release of acetylcholine. Autoantibodies against P/Q-type voltage-gated calcium channels (VGCC) are detected in 85% of patients with LEMS. In addition, autoantibodies to synaptotagmin, an M1-type muscarinic acetylcholine receptor and SOX1 are also found in the sera of patients with LEMS. LEMS is closely associated with small cell lung cancer (SCLC) in 50-60% of patients. Patients with SCLC who have anti-VGCC antibodies have been reported to have a favorable prognosis. In contrast to paraneoplatic LEMS, other forms of LEMS may have an autoimmune aspect because of the established association between human leukocyte antigen and a family history of other autoimmune disorders in this condition. The clinical features of LEMS include proximal weakness, areflexia, ptosis, cerebellar ataxia and autonomic dysfunction. The findings of electrophysiological examination show that LEMS is characterized by compound muscle action potential potentials with a low amplitude and increment upon repetitive nerve stimulation at a high rate. Tumor removal is the primary treatment of LEMS. The efficacy of 3,4-diaminopyridine for the treatment of LEMS has also been established. Patients with LEMS require the immunotherapies such as plasma exchange and the administration of high doses of immunoglobulin and prednisolone.

AB - Lambert-Eaton myasthenic syndrome (LEMS) is a neuromuscular disorder in which autoantibodies inhibit the presynaptic release of acetylcholine. Autoantibodies against P/Q-type voltage-gated calcium channels (VGCC) are detected in 85% of patients with LEMS. In addition, autoantibodies to synaptotagmin, an M1-type muscarinic acetylcholine receptor and SOX1 are also found in the sera of patients with LEMS. LEMS is closely associated with small cell lung cancer (SCLC) in 50-60% of patients. Patients with SCLC who have anti-VGCC antibodies have been reported to have a favorable prognosis. In contrast to paraneoplatic LEMS, other forms of LEMS may have an autoimmune aspect because of the established association between human leukocyte antigen and a family history of other autoimmune disorders in this condition. The clinical features of LEMS include proximal weakness, areflexia, ptosis, cerebellar ataxia and autonomic dysfunction. The findings of electrophysiological examination show that LEMS is characterized by compound muscle action potential potentials with a low amplitude and increment upon repetitive nerve stimulation at a high rate. Tumor removal is the primary treatment of LEMS. The efficacy of 3,4-diaminopyridine for the treatment of LEMS has also been established. Patients with LEMS require the immunotherapies such as plasma exchange and the administration of high doses of immunoglobulin and prednisolone.

KW - Autoantibodies

KW - P/Q-type voltage-gated calcium channels

KW - Paraneoplastic

KW - Small cell lung cancer

KW - Synaptotagmin

UR - http://www.scopus.com/inward/record.url?scp=77951616801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951616801&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 419

EP - 426

JO - Brain and Nerve

JF - Brain and Nerve

SN - 0006-8969

IS - 4

ER -